- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.09. | Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants | ||
| 17.09. | SBTi approves Piramal Pharma's GHG reduction targets | ||
| 16.09. | Boehringer seeks approval for lung fibrosis drug following Phase III win | ||
| 16.09. | Disease modifiers may take over PAH landscape, says Cereno CEO | ||
| 16.09. | Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss | ||
| 16.09. | Pioneering ePRO and eCOA innovations for next-generation clinical trials | ||
| 16.09. | China grants BTD to Blenrep with BorDex for multiple myeloma | ||
| 16.09. | FDA approves Roche's Ocrevus Zunovo with Halozyme Enhanze delivery tech | ||
| 16.09. | After the Lykos debacle, what's next for psychedelic therapies? | ||
| 16.09. | Minimizing risks in pharmaceutical supply chains: what you need to know | ||
| 16.09. | Regeneron's Dupixent approved as first adolescent CRSwNP treatment | ||
| 16.09. | Lilly's EBGLYSS gains FDA approval for patients aged 12 and older | ||
| 13.09. | Oncternal stock crashes by 60% as it lays off staff and scraps trials | ||
| 13.09. | Cidara axes 30% of staff to focus on flu prevention drug | ||
| 13.09. | Sobi and Enable Injections partner for Aspaveli distribution | ||
| 13.09. | FDA approves Roche's Tecentriq Hybreza for cancer | ||
| 13.09. | Into the unknown: How quickly can vaccines be developed for Disease X | ||
| 13.09. | Sanofi signs radioligand therapy licensing deal for rare cancers | ||
| 13.09. | Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland | ||
| 12.09. | Bavarian Nordic promises two million mpox vaccines for Africa by end of 2024 | ||
| 12.09. | Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation | ||
| 12.09. | India's CDSCO suspends Entod's licence for PresVu eye drops | ||
| 12.09. | FDA grants breakthrough therapy designation to Neuraptive's NTX-001 | ||
| 12.09. | FDA approves Johnson & Johnson's TREMFYA for ulcerative colitis | ||
| 11.09. | EASD 2024: Are tetra-agonists the future of metabolic diseases treatment? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
